Acute Myeloid Leukemia Clinical Trials in Memphis, Tennessee
10 studies are recruiting for acute myeloid leukemia in Memphis, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of …
- Stage
- Phase 2
- Ages
- 18 to 59
- Site
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee
- Locations
- 186 in total
- Run by
- National Cancer Institute (NCI)
-
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabi…
- Stage
- Phase 2
- Ages
- 18 to 59
- Site
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee
- Locations
- 226 in total
- Run by
- National Cancer Institute (NCI)
-
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrom…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee
- Locations
- 349 in total
- Run by
- National Cancer Institute (NCI)
-
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed in…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee
- Locations
- 227 in total
- Run by
- National Cancer Institute (NCI)
-
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia (AML). Primary Objectives: * Establish the tolerability adding venetoclax to standard chemotherapy …
- Stage
- Phase 2
- Ages
- 0 to 21
- Site
- St. Jude Children's Research Hospital, Memphis, Tennessee
- Locations
- 10 in total
- Run by
- St. Jude Children's Research Hospital
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
This is a single-arm pilot clinical trial evaluating dalbavancin-based prophylaxis in children and adolescents with acute myeloid leukemia or relapsed lymphoblastic leukemia receiving myelosuppressive chemotherapy. Primary objective: - To estimate the rate of bacterial bloodstream infection in pedi…
- Stage
- Phase 1
- Ages
- Up to 25
- Site
- St. Jude Children's Research Hospital, Memphis, Tennessee
- Run by
- St. Jude Children's Research Hospital
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informat…
- Stage
- Phase 1
- Ages
- Up to 22
- Site
- Saint Jude Children's Research Hospital, Memphis, Tennessee
- Locations
- 184 in total
- Run by
- PedAL BCU, LLC
-
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or…
- Stage
- Phase 3
- Ages
- 0 to 21
- Site
- St. Jude Children's Research Hospital, Memphis, Tennessee
- Locations
- 90 in total
- Run by
- PedAL BCU, LLC
-
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of eltanexor in combination with venetoclax for the treatment of patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to pre…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Baptist Health Care Corporation, Memphis, Tennessee
- Locations
- 2 in total
- Run by
- Vanderbilt-Ingram Cancer Center
-
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
This is a Phase 1, open label, multicenter, dose finding study with dose expansion intended to evaluate the safety and tolerability of talazoparib in combination with conventional chemotherapy. Preliminary estimates of efficacy will be obtain through a dose expansion cohort receiving the maximum to…
- Stage
- Phase 1
- Ages
- Up to 21
- Site
- St. Jude Children's Research Hospital, Memphis, Tennessee
- Locations
- 9 in total
- Run by
- Norman J. Lacayo
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.